Marc M. Lemaitre, PhDPrincipal at ML ConsultSpeaker
Profile
I have a very long experience with oligonucleotide therapeutics, focusing on CMC. I have over 20 years of experience in the fields of Biotech research, production, QA, development in particular with oligonucleotides for therapeutic applications. As CEO of Girindus America [now Avecia Cincinnati, I supervised the manufacturing of more than 30 oligonucleotides for clinical trials. I authored several CMC parts IND and/or tIMPD.
Agenda Sessions
Drug Substance and Drug Product and How CMC Early in the Discovery Lifecycle Can Help
, 09:10View Session

